SINEW PHARMA

SINEW is actively exploring partnerships for licensing, co-development and strategic alliance. Meanwhile, our patent strategy ensures the secure protection of pipeline assets, and we are open to discussions regarding intellectual property transfer. SINEW is also seeking experienced partners for regional regulatory application, pharmaceutical marketing and channel distribution to enable market and patient accessibility... SINEW is adopting a comparable strategy as other pharmaceutical companies of concurrently developing several new drugs for MASH. This includes the development of SNP-610, a drug featuring an innovative combination of active ingredients for a new indication, as well as SNP-630, a new chemical entity (NCE). The rationale is to increase the probability of success for MASH drug development, as it is not yet confirmed whether the development of a single-target drug can completely cure MASH, a disease with complex etiology. Up until now, no drug has been approved globally..

Also known as: SINEW PHARMA INC

Primary location: Taipei Taiwan